Colossal Biosciences acquired Viagen Pets & Equine, a cloning and biobanking specialist, integrating Viagen’s reproductive and preservation capabilities into Colossal’s broader species‑preservation and de‑extinction strategy. Viagen, which has cloned multiple species and maintains a biobank of over 40 species including threatened animals, will continue to operate from its Texas base with existing staff. Colossal said the deal strengthens its cloning technology stack and conservation mission. The acquisition follows Colossal’s recent funding expansion and underscores how synthetic biology and conservation startups are consolidating capabilities—wet lab, biobanking and reproduction services—to pursue large, long‑term biodiversity projects.